Cancer Drugs And Medicare: Range Of Impacts Expected From IRA Price Reforms

 
• By Cathy Kelly

Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.

Oral Cancer Drugs The Poster Child For IRA-Driven Challenges To Innovation? • Source: Shutterstock

More from Market Access

More from Pink Sheet